How to Appeal a GLP-1 Prior Authorization Denial: Internal, External, and ERISA Pathways

Roughly half of first-time prior authorization (PA) requests for Wegovy and Zepbound are denied on the initial submission, and the most common reason is not that the patient is ineligible — it is that the chart did not document the criteria the payer wanted to see. Appeals are won and lost on documentation. This article walks the four pathways available when a GLP-1 prescription is denied (internal appeal, external IRO review, ERISA self-funded plan appeal, and state insurance commissioner complaint), the specific documents that move the needle, and the trial evidence to cite for the three comorbidity carve-outs that survive in plans that otherwise exclude weight-loss drugs: cardiovascular risk reduction (SELECT^[1]), obstructive sleep apnea (SURMOUNT-OSA^[4]), and type 2 diabetes with obesity (STEP-2^[5]). None of this constitutes legal advice; for plan-specific deadlines and procedural rights, read your Summary Plan Description (SPD) and the denial letter carefully.

Why GLP-1 prior auths get denied

Most denials fall into one of four buckets. Identifying which one applies to your letter determines what the appeal needs to contain.

1. Step therapy not documented. The plan requires prior trial and failure of one or more lower-tier weight-loss drugs (typically phentermine, phentermine/topiramate, naltrexone/bupropion, or orlistat) or a documented contraindication to each. The chart did not include the dates, dose, duration, and reason the patient stopped each prior agent. Aetna's Wegovy pharmacy clinical policy and most BCBS plans use this construction.
2. BMI threshold not met or not documented.The plan requires BMI ≥ 30 alone, or ≥ 27 with a weight-related comorbidity. The chart did not document a measured (not self-reported) BMI at or above the threshold within the lookback window (often 6 or 12 months).
3. Categorical exclusion of weight-loss drugs.The plan's formulary excludes anti-obesity medications entirely. There may still be a carve-out for the FDA-labeled comorbidity indications (Wegovy for cardiovascular risk reduction, Zepbound for moderate-to-severe OSA, Mounjaro or Ozempic for type 2 diabetes) that the denial letter did not mention.
4. Documentation incomplete. Missing prescriber attestation that the patient is enrolled in a behavioral lifestyle program, missing comorbidity ICD-10 codes on the claim, missing 6-month weight history, missing prior failed-therapy notes. Often the easiest category to fix.

The internal appeal: deadlines and contents

For fully insured commercial plans regulated under the Affordable Care Act, the typical internal appeal deadline is 180 days from the denial notice for plans following the federal floor, though many plans set shorter windows (commonly 30, 60, or 90 days for the standard appeal). The denial letter must state the exact deadline; if it does not, request it in writing. There are usually two internal review levels before external review is available.

A competent internal appeal letter contains:

• Member identification block. Name, date of birth, member ID, group number, claim or PA reference number from the denial letter.
• The specific denial reason being appealed.Quote the denial letter verbatim. If the letter cites multiple reasons, address each one separately.
• BMI history with measurement dates. Three to six dated BMI measurements over the most recent 12 months, from in-clinic encounters (not self-reported).
• Comorbidity ICD-10 codes. The big three for GLP-1 appeals: E66.01 (severe obesity due to excess calories, BMI 35.0–39.9), E66.811 (obesity, Class 1; BMI 30.0–34.9), E11.65 (type 2 diabetes with hyperglycemia), E78.5 (hyperlipidemia, unspecified), I10 (essential hypertension), G47.33 (obstructive sleep apnea), Z68.41–Z68.45 (BMI 40.0 and above, adult).
• Prior failed therapy table. For each previously tried agent: drug name, start date, end date, maximum dose, and the reason for discontinuation (intolerance, inadequate response, contraindication). Pharmacy fill records, when attached, are usually decisive.
• The letter of medical necessity (LMN).Discussed in its own section below.
• Supporting trial citations. SELECT for CV risk reduction in patients with established atherosclerotic cardiovascular disease^[1], SURMOUNT-OSA for OSA^[4], STEP-2 for the T2D and obesity overlap^[5], STEP-1 and SURMOUNT-1 for the underlying weight-loss efficacy^[2][3].

The external appeal: state insurance commissioner and the IRO

After exhausting internal appeals, ACA-regulated plans must offer an external review by an Independent Review Organization (IRO)^[8]. The IRO is a third-party medical-review entity contracted either by the plan or by the state. The IRO's decision is binding on the plan. State-administered external review (most states) runs through the state department of insurance or insurance commissioner; federal external review (some states and certain plan types) runs through HHS.

Practical points:

• External review is free to the member.The plan pays the IRO fee.
• The external review window is typically 4 months from the final internal denial. Some states set shorter windows; the denial-of-appeal letter must state the specific deadline.
• Expedited external review is available when a delay would seriously jeopardize health (rarely applicable to elective obesity pharmacotherapy, but can apply when a comorbidity is severe and progressing).
• The IRO reads everything the internal reviewers saw plus anything new you submit. Treat the external-review packet as a full re-submission, not a patch on the internal appeal.
• State insurance commissioner complaintsare separate from external review and can be filed in parallel. A complaint can sometimes prompt a faster internal re-review, particularly when the denial letter omitted required disclosures.

ERISA self-funded plans: a different pathway

Self-funded employer plans are regulated under ERISA (the Employee Retirement Income Security Act of 1974) rather than state insurance law. The administrator (Aetna, Cigna, UHC, BCBS) processes claims but the employer bears the financial risk. ERISA-regulated plans follow the federal claims procedure regulation at 29 CFR 2560.503-1^[7], which sets minimum timing standards and the right to receive, on request, all documents relevant to the claim.

Key ERISA-specific points:

• State external review and state insurance commissioner complaints generally do not apply to true ERISA self-funded plans. The remedy after internal appeal exhaustion is a civil action in federal court under ERISA § 502(a). Practically, most plans voluntarily contract with an IRO regardless.
• The Department of Labor (DOL) Employee Benefits Security Administration enforces the ERISA claims regulation. DOL will not adjudicate the medical question but will investigate procedural violations (missed deadlines, failure to disclose plan documents, denial letters missing required content).
• Request the Summary Plan Description (SPD) and the full plan document in writing immediately after the denial. ERISA requires the plan to provide both within 30 days; failure to provide can trigger statutory penalties.
• Document the administrative record carefully.In any subsequent federal-court ERISA action, the court typically reviews only the record that was before the plan at the time of the final denial. Anything not submitted during internal appeals usually cannot be added later.

Documentation that wins appeals

Across every plan type, four documentation elements move appeals more than any others:

1. A measured BMI history with at least 3 dated points in the last 12 months, all from in-clinic encounters, all above the policy threshold. Self-reported weights are frequently challenged.
2. Specific comorbidity ICD-10 codes on the claim AND in the chart. The reviewer pulls the diagnosis codes from the claim header; if E11.65 or G47.33 is not on the claim, the comorbidity carve-out will not trigger automatically.
3. A prior-failed-therapy table with pharmacy fill records. Naming the drugs is necessary but not sufficient; the pharmacy fills (or documented prescriber notes when the patient discontinued before filling) establish that the trial actually happened.
4. A letter of medical necessity signed and dated by the prescriber. See structure below.

Comorbidity evidence to cite

When the patient has an FDA-labeled comorbidity indication, the appeal becomes substantively stronger because the prescription is no longer a pure weight-loss request.

• Established cardiovascular disease (Wegovy). The SELECT trial^[1] randomized 17,604 patients with established ASCVD and BMI ≥ 27 (no diabetes) to semaglutide 2.4 mg or placebo and showed a 20% relative reduction in major adverse cardiovascular events (cardiovascular death, nonfatal MI, or nonfatal stroke). The Wegovy FDA label was updated in March 2024 to add the cardiovascular risk reduction indication. For patients with a history of MI, stroke, peripheral arterial disease, or symptomatic coronary disease, an appeal on the CV indication often succeeds where the obesity-alone appeal would not.
• Moderate-to-severe obstructive sleep apnea (Zepbound). SURMOUNT-OSA^[4] showed tirzepatide reduced the apnea-hypopnea index in patients with moderate-to-severe OSA and obesity. The Zepbound FDA label was updated in December 2024 to add the OSA indication. A polysomnography or home sleep apnea test (HSAT) report documenting AHI in the moderate-to-severe range, plus the G47.33 ICD-10 code, anchors this appeal.
• Type 2 diabetes plus obesity (Wegovy or Zepbound). STEP-2^[5] demonstrated semaglutide 2.4 mg efficacy specifically in the T2D and obesity overlap population. Many plans permit a GLP-1 for T2D under the diabetes benefit even when they exclude anti-obesity drugs. Code combinations of E11.x with E66.01 or Z68.4x establish the dual-indication patient.

The letter of medical necessity (LMN)

A defensible LMN is one page, signed by the prescriber on clinic letterhead, dated, and structured as follows:

1. Patient identification — name, DOB, member ID.
2. Diagnoses with ICD-10 codes — obesity class and comorbidities (E66.01 or E66.811, plus E11.65, I10, E78.5, G47.33 as applicable). Match these to the claim header exactly.
3. Measured BMI and weight history — current BMI and three prior dated measurements.
4. Prior weight-loss interventions tried and outcomes — lifestyle program (12+ weeks documented), phentermine, phentermine/topiramate, naltrexone/bupropion, orlistat, as applicable, with start and stop dates, dose, and the reason discontinued.
5. The clinical rationale for this specific medication — one paragraph linking the patient's comorbidity profile to the FDA-labeled indication, with one or two PMID citations from SELECT, SURMOUNT-OSA, STEP-2, STEP-1, or SURMOUNT-1.
6. The monitoring plan — titration schedule, follow-up cadence (typically every 4–8 weeks during titration, then quarterly), GI side-effect management per Wharton 2022^[6].

Payer-specific gotchas

• Aetna. The Wegovy pharmacy clinical policy typically requires 6 months of documented lifestyle intervention and trial or contraindication to one prior weight-loss agent. The 6 months can be retrospective. See our Aetna GLP-1 prior authorization guide for the current criteria.
• UnitedHealthcare. Many UHC commercial plans require ongoing enrollment in a designated weight-management program (registered dietitian, structured behavioral program, or bariatric clinic). The enrollment letter is the single document most frequently missing. See our UHC GLP-1 prior authorization guide.
• BCBS (state variability). Each BCBS licensee writes its own policy; criteria vary significantly across states. Anthem in CA, NY, and CO publishes different step-therapy requirements than Highmark BCBS in PA, BCBS of Texas, or Florida Blue. See our Anthem GLP-1 PA guide.
• Cigna. The IP0206 weight-loss GLP-1 policy typically requires BMI ≥ 30 (or ≥ 27 with comorbidity), a documented lifestyle program, and continued use is conditioned on a minimum percent weight loss at the reauthorization window. See our Cigna GLP-1 PA guide.

When to bring in the prescriber's billing team

For complex denials — particularly second-level internal appeals, exception requests on closed formularies, and coordination of a peer-to-peer review — the prescriber's billing or revenue-cycle team often has direct payer-contact channels patients do not. Most large endocrinology and obesity-medicine clinics employ a PA specialist. Ask whether your clinic has one, what their process is, and what documentation they need from you. Peer-to-peer reviews (a phone call between the prescriber and a payer medical director) are most useful when the denial cites a clinical question rather than a policy criterion.

State-mandated coverage and partial mandates

A small but growing number of states have enacted partial mandates requiring state-regulated commercial plans (and in some cases Medicaid) to cover FDA-approved anti-obesity medications under specified circumstances. The patchwork evolves quickly and is plan-type-specific: state insurance law generally does not reach self-funded ERISA plans. Examples of states with relevant statutes or Medicaid policy wins worth checking against your plan type:

• North Carolina — state employee health plan (SHP) coverage has changed multiple times in recent years; verify the current SHP formulary directly.
• Oklahoma — Medicaid (SoonerCare) has a carve-out PA pathway for Wegovy in patients with established cardiovascular disease, age and BMI criteria apply.
• See our full coverage landscape article and individual state Medicaid pages for current criteria.

Bottom line

• Identify which of the four denial buckets applies (step therapy, BMI threshold, categorical exclusion, or documentation gap) before writing the appeal.
• The internal appeal window is typically 30–180 days from denial; read the letter for the exact deadline.
• After internal exhaustion, ACA-regulated fully insured plans must offer external review by an IRO^[8]. ERISA self-funded plans follow the federal claims regulation^[7] and remedies escalate to DOL investigation or federal court.
• Documentation wins appeals: dated measured BMI history, ICD-10 codes on the claim, prior-failed-therapy table with pharmacy fills, and a one-page letter of medical necessity.
• For patients with established CVD, OSA, or T2D, cite SELECT^[1], SURMOUNT-OSA^[4], and STEP-2^[5] respectively; comorbidity-indication appeals materially outperform pure-obesity appeals on exclusion-plan denials.

Related research

• What to do when your plan drops GLP-1 coverage mid-treatment — the parallel playbook for formulary changes (not PA denials)
• Aetna GLP-1 prior authorization guide
• UnitedHealthcare GLP-1 prior authorization guide
• Cigna GLP-1 prior authorization guide
• Anthem GLP-1 prior authorization guide
• GLP-1 coverage across Medicare, Medicaid, and commercial plans
• Cheapest GLP-1 options without insurance — for the parallel cash-pay pathway while appeals run

Important disclaimer. This article is educational and does not constitute legal, medical, or insurance advice. Appeal deadlines and procedural rights are plan-specific and state-specific; read the denial letter and your Summary Plan Description carefully and consult the prescribing clinician and, where appropriate, a licensed attorney or the state insurance department. PMIDs and federal regulatory citations were independently verified on 2026-05-28. Federal and state regulatory landscapes change; verify current rules at the time of your appeal. Mention of specific payers reflects publicly available clinical policy documents and does not imply endorsement or affiliation.

Last verified: 2026-05-28. Next review: every 6 months, or sooner if material federal or state regulatory changes are announced.